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Abstract
Background: Chromogenic in situ hybridization (CISH) is fast becoming a well established technique for easy and
sensitive determination of HER2 gene status in breast cancer. However, for the chromogenic method to achieve
status as a safe and reliable technique, the method needs to be validated against already known and validated
FISH techniques.
Methods: Here it is reported from a comparative study where HER2 gene status obtained by HER2 CISH
pharmDx™ Kit was compared to HER2 gene status obtained by the FDA approved HER2 FISH pharmDx™ Kit and
the PathVysion HER-2 DNA probe Kit. The study included 365 formalin fixed and paraffin-embedded invasive breast
cancer tissue specimens collected consecutively at a US reference laboratory.
Results: The data obtained revealed an overall HER2 status concordance of approximately 98% for comparisons of
HER2 CISH pharmDx™ Kit to both HER2 FISH pharmDx™ Kit and PathVysion HER-2 DNA Probe Kit.
Conclusions: The concordance between results obtained using the recently FDA approved HER2 CISH pharmDx™
Kit with previously FDA approved FISH techniques for HER2 gene status determination indicate that the HER2 CISH
pharmDx™ Kit is a reliable chromogenic alternative to fluorescence-based methods.
Background
HER2 (Human Epidermal Growth Factor Receptor 2) is
an important marker for invasive breast cancer. The
assessment of the HER2 expression level is routinely
done by examining protein expression and/or gene
expression levels in formalin-fixed and paraffin-
embedded (FFPE) histological sections. Overexpression
of HER2 protein and/or HER2 (Human Epidermal
Growth Factor Receptor 2 Gene) amplification is
observed in approximately 22% of human breast cancers
[1] and has been shown to be a marker of poor prog-
nosis [2] and to predict benefit from treatment with the
antibody based drug Herceptin (Genentech, San Fran-
cisco, CA, USA) [3].
Tissue based assessment of HER2 protein expression
levels is commonly achieved using immunohistochemistry
(IHC), whereas tissue based analysis of HER2 amplification
is mostly done by in situ hybridization (ISH) techniques
either fluorescence (FISH) [4] or chromogenic (CISH or
SISH) [5]. In ISH the specific recognition of HER2 target
sequences in the nuclei of tumor cells is done by fluores-
cence- or hapten-labeled sequence pairing probes. Imple-
mentation of CISH for determination of HER2
amplification in breast cancer has some advantages com-
pared to FISH based detection [6-9]. Chromogenic signals
do not fade over time and can therefore be archived and
used for re-evaluation or retrospective studies. Further-
more, chromogenic visualization enables bright-field
microscopy and easy access to tissue morphology to
directly determine the appropriate tumor area for
evaluation.
To implement CISH in the anatomical pathological
laboratories for determination of HER2 status in breast
cancer the technique needs to be safe and reliable [10]. * Correspondence: jens.mollerup@dako.com
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obtained by the CISH method against results obtained
from already known and validated HER2 FISH techni-
ques. In this paper data is reported from the comparison
of 365 breast cancer specimens using a new dual color
HER2 CISH method (HER2 CISH pharmDx™ Kit, Dako
Denmark A/S, Glostrup, Denmark) with two well estab-
lished and FDA approved HER2 FISH techniques; HER2
FISH pharmDx™ Kit (Dako Denmark A/S, Glostrup,
Denmark) and PathVysion HER-2 DNA Probe Kit
(Abbot Laboratories, Illinois, USA).
Methods
Specimens
The study included 365 FFPE invasive breast cancer tis-
sue specimens with known fixation history (10% neutral
buffered formalin, 18-24 h). The specimens were col-
l e c t e dc o n s e c u t i v e l ya taU Sr e f e r e n c el a b o r a t o r ya n d
the first 304 specimens were included irrespective of
HercepTest™ (Dako Denmark A/S, Glostrup, Denmark)
IHC score and additional 61 specimens were included
based on a IHC HER2 2+ score as determined by Her-
cepTest™ Serial sections (5 μm) were cut from each
specimen and stained with H&E, HercepTest™ for
HER2 protein expresion, HER2 CISH pharmDx™ Kit
(Dako Denmark A/S), HER2 FISH pharmDx™ Kit
(Dako Denmark A/S) and PathVysion HER-2 DNA
Probe Kit (Abbott Laboratories, Illinois, USA). Speci-
mens were not individually identifiable and it was
impossible to trace the identity of the patients. The
study was performed in accordance with the current
version of the World Medical Association Declaration of
Helsinki and approval from an Institutional Review
Board (Copernicus Group, Inc.) was granted prior to
study start. Evaluation of specimens were performed by
three different technologists for the three ISH tests and
subsequently reviewed by the pathologists. One patholo-
gist reviewed test results obtained with PathVysion
HER-2 DNA Probe Kit and HER2 CISH pharmDx™ Kit
with several months in between and another pathologist
reviewed test results obtained with HER2 FISH
pharmDx™ Kit. Knowledge of test results was not
shared between technologists or between pathologists.
CISH testing
HER2 CISH staining was performed according to the
manufactures instructions (Dako Denmark A/S) at the
US reference laboratory. In short, specimens were sub-
jected to heat-pre-treatment (microwave oven) and pep-
sin digestion at 37°C to prepare the tissue for probe
hybridization. Denaturation for 5 min at 82°C and over-
night hybridization at 45°C were performed simulta-
neously for the HER2/Texas Red labeled DNA probe
and the CEN-17/FITC labeled PNA probe using a
Hybridizer (Dako Denmark A/S). Specimens were sub-
jected to stringent wash at 65°C for 10 min before trans-
fer to a CISH wash buffer. The signals from the
fluorescent probes were converted to chromogenic sig-
nals in an IHC staining reaction performed on an auto-
mated platform (Autostainer Plus, Dako Denmark A/S).
The immunohistochemical staining included blocking of
endogeneous peroxidase activity, incubation with horse-
radish peroxidase conjugated anti-FITC and alkaline
phosphatase conjugated anti-Texas Red antibodies fol-
lowed by development of chromogenic signals using red
a n db l u ec h r o m o g e n s .T h es l i d e sw e r ec o u n t e r s t a i n e d
with hematoxylin and mounted in a permanent mount-
ing medium.
HER2 CISH stained slides were interpreted using a
bright field microscope with 40× and 60× objectives.
The HER2/CEN-17 ratio was calculated based on the
enumeration of 20 nuclei from the invasive tumor area.
Based on ratio, the specimens were categorized into
amplified (HER2/CEN-17 2.0) or non-amplified (HER2/
CEN-17 < 2.0) categories. Specimens with a ratio
between 1.8 and 2.2 (borderline cases) were subjected to
additional enumeration of 20n u c l e ia n dt h er a t i ow a s
then recalculated for the 40 nuclei to determine if
amplification was present or not. Normal cells within
the specimen served as an internal control for staining
success. Normal cells should exhibit the ratio expected
for normal diploid cells with a one to one relationship
of red and blue signals.
FISH testing
HER2 FISH pharmDx™ was performed according to the
manufacturer’s instructions at Dako Denmark A/S and
FISH using PathVysion HER-2 DNA Probe Kit was per-
formed according to an internally validated procedure at
the US reference laboratory.
HER2 status
In accordance with FDA approved guidelines for deter-
mination of HER2 status HER2/CEN-17 ratios obtained
by CISH and FISH were translated to a HER2 gene sta-
tus of amplified when the HER2/CEN-17 ratio was
higher than or equal to 2.0 or non-amplified when the
HER2/CEN-17 ratio was below 2.0.
IHC testing
All specimens were tested at the US reference laboratory
using HercepTest™ as per the manufacturer’si n s t r u c -
tions to determine the IHC HER2 score.
Statistics
IBM SPSS Statistics were used for statistical work (SPSS
Inc., Chicago, IL). Agreement calculations were reported
with 95% confidence limits based on the binomial
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[11] as calculated by the PROPOR plug-in.
Results
HER2 immunohistochemistry scores of specimens
included
A total of 365 breast cancer specimens were included in
this investigation. An overview of the HER2 IHC scores
obtained from HercepTest™ staining is provided in
Table 1 for the entire population and for the specimens
sampled consecutively. Among the 304 consecutively
collected specimens 10.5% were HER2 3+, 18.8% were
HER2 2+ and the remaining 70.8% were HER2 0 or 1+.
In a recent meta-analysis the median percentage of spe-
cimens in the IHC 2+ and IHC 3+ category were found
at 12.0% and 16.2% [12] which indicate a low percentage
of IHC 3+ specimens in this investigation.
Frequencies of amplified and non-amplified specimens
Frequencies of HER2 amplified and non-amplified test
results found by HER2 CISH, HER2 FISH and PathVy-
sion FISH are presented in Table 2 for all specimens. For
the consecutively collected specimens only 10.8% of spe-
cimens with a successful test result were amplified by
HER2 CISH, 11.4% were amplified by HER2 FISH and
11.0% were amplified by PathVysion FISH (data not
shown). Figure 1 includes images illustrating a non-
amplified and a cluster amplified breast cancer specimen
stained by HER2 CISH pharmDx™ Kit. In both panels
tumor cells having distinctive blue dots are observed cor-
responding to the reference CEN-17 probe signals (Fig-
ure 1). In the non-amplified specimen (right panel) single
red dots corresponding to the HER2 signals are apparent.
The amplified specimen (left panel) have cluster amplifi-
cation in which red signals are overlapping, but some sin-
gle red signals are also visible in some tumor cells.
HER2 status agreement
As indicated in Table 2, 13 specimens lack a HER2 CISH
result and seven specimens lack a HER2 FISH result.
Three of these specimens are overlapping and therefore,
348 specimens were eligible for comparison between
HER2 CISH and HER2 FISH. Agreement calculations
revealed an overall agreement of 98.3% (CI95: 96.5%;
99.3%) with positive agreement of 93.2% (CI95: 82.9%;
98.0%) and negative agreement of 99.0% (CI95: 97.4%;
99.7%) when comparing HER2 CISH and HER2 FISH
(Table 3). The Kappa value was found at 0.92 [13]. McNe-
mar’s test for a systematic bias between HER2 CISH and
HER2 FISH revealed a non-significant two-tailed p value
of 1.00 showing that no bias was present [14]. Three of
the six discordant cases for the comparison between HER2
CISH and HER2 FISH (Table 3) were HercepTest™ IHC
2+ equivocal cases, and the remaining three were 0, 1+
and 3+, respectively. The discordant cases had a HER2/
CEN-17 ratio very close to or within the borderline area
defined from 1.8 and 2.2 for at least one of the three meth-
ods performed. As indicated in Table 2, there are four spe-
cimens that lack a PathVysion FISH result and two of
these specimens are overlapping with HER2 CISH result-
ing in agreement calculations based on a total of 350 spe-
cimens for this comparison. The overall HER2 status
agreement between HER2 CISH and PathVysion FISH was
97.7% (CI95: 95.7%; 98.9%). Positive agreement was 90.9%
(CI95: 79.8%; 96.9%) and negative agreement was 98.7%
(CI95: 96.9%; 99.6%) (Table 4). The Kappa value was
found at 0.90 [13]. McNemar’s test for a systematic bias
between HER2 CISH and PathVysion FISH revealed a
non-significant two-tailed p value of 1.00 indicating the
Table 1 IHC score frequencies of specimens included for the entire population studied including specimens sampled
consecutively
Consecutive and IHC 2+ specimens Consecutive specimens only
HercepTest™ Frequency Percent Frequency Percent
0 102 27.9 102 33.5
1+ 113 31.0 113 37.2
2+ 118 32.3 57 18.8
3+ 32 8.8 32 10.5
Total 365 100 304 100
Table 2 HER2 gene status frequencies of successful test
results divided by assay
Assay HER2 status Frequency Percent
HER2 CISH pharmDx™ Non-amplified 307 87.2
Amplified 45 12.8
Total 352 100.0
Missing 13
HER2 FISH pharmDx™ Non-amplified 314 87.7
Amplified 44 12.3
Total 358 100.0
Missing 7
PathVysion HER-2 FISH Non-amplified 317 87.8
Amplified 44 12.2
Total 361 100.0
Missing 4
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comparison between HER2 CISH and PathVysion FISH
(Table 4) were HercepTest™ IHC 2+ equivocal cases, and
the remaining three were 3+. For the three IHC 3+ discor-
dant cases cluster amplification of blue (CEN-17) signals
w a so b s e r v e dt h a tc o v e r e dr e d( HER2) signals or made
them difficult to see. In these cases the blue signals in the
normal cells surrounding the tumor cells were clear and
distinct and cases could therefore pass the quality control.
Therefore, in cases with cluster amplification of blue sig-
nals additional caution should be taken during interpreta-
tion and results from other test methods such as IHC or
FISH should be included before a final HER2 status is
given.
Success rates
Final success rates were determined after allowing for
two staining runs. Of the 13 cases with a missing HER2
CISH test result (Table 2) the second staining run was
not performed in four cases and, therefore, the success
rate for HER2 CISH was 97.5% (352/361*100). The suc-
cess rates for HER2 FISH and PathVysion FISH were
98.4 and 98.9%, respectively.
Exploratory analysis of copy numbers and ratio
Exploratory analysis of HER2/CEN-17 ratios was per-
formed by plotting ratios obtained by HER2 CISH as a
function of ratios obtained by HER2 FISH (Figure 2) or
PathVysion FISH (Figure 3). The plot of the ratio data
revealed a good correlation between the HER2 CISH ratio
and the ratios obtained by the two HER2 FISH assays.
Since the data showed heteroscedasticity with apparent
elevated variances at higher ratios linear regression was
not carried out. The plots of HER2/CEN-17 ratios in Fig-
ure 2 and Figure 3 also reveal that lower HER2 CISH
ratios are observed at ratios above 3.0 compared to ratios
obtained by FISH. During the exploratory analysis mean
HER2/CEN-17 ratios and mean HER2 and CEN-17 signal
copy numbers (normalized to 20 nuclei) were calculated
for all three assays and tabulated for comparison for all
the valid specimens (Table 5). In order to evaluate HER2
CISH assay performance closer to the cut-off this data
were also presented for all valid specimens having a CISH
HER2/CEN-17 ratio below 3.0 (Table 6). Generally the
standard deviations on copy numbers and HER2/CEN-17
ratios for HER2 CISH seemed lower compared to HER2
FISH and PathVysion FISH (Table 5 and Table 6). The
comparison also revealed that significantly higher HER2/
CEN-17 ratios and higher CEN-17 signal copy numbers
were observed for HER2 CISH compared to HER2 FISH
and PathVysion FISH, whereas no significant difference
were observed between HER2 signals (Table 5). Interest-
ingly, the examination of cases with a HER2/CEN-17 ratio
below 3.0 revealed that significant higher HER2 and CEN-
Figure 1 Images of specimens stained with HER2 CISH pharmDx™ Kit. Images representing a HER2 gene amplified (HER2/CEN-17 ratio 2.0)
specimen to the left and a non-amplified specimen (HER2/CEN-17 ratio < 2.0) to the right
Table 3 Cross tabulation of HER2 gene status for CISH
versus Dako FISH.
HER2 FISH pharmDx™
Non-amplified Amplified Total
HER2 CISH pharmDx™ Non-amplified 301 3 304
Amplified 3 41 44
Total 304 44 348
Two tailed 95% confidence intervals are based on the binomial distribution.
Overall agreement: (342/348 × 100) = 98.3% (CI95: 96.5%; 99.3%), Positive
agreement: (41/44 × 100) = 93.2% (CI95: 82.9%; 98.0%), Negative agreement:
(301/304 × 100) = 99.0% (CI95: 97.4%; 99.7%) and Kappa: 0.92 (SE: 0.03)
Table 4 Cross tabulation of HER2 gene status for CISH
versus PathVysion FISH.
PathVysion HER-2 FISH
Non-amplified Amplified Total
HER2 CISH pharmDx™ Non-amplified 302 4 306
Amplified 4 40 44
Total 306 44 350
Two tailed 95% confidence intervals are based on the binomial distribution.
Overall agreement: (342/350 × 100) = 97.7% (CI95: 95.7%; 98.9%), Positive
agreement: (40/44 × 100) = 90.9% (CI95: 79.8%; 96.9%), Negative agreement:
(302/306 × 100) = 98.7% (CI95: 96.9%; 99.6%) and Kappa: 0.90 (SE: 0.04)
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Page 4 of 7Figure 2 Plot of HER2/CEN-17 ratios obtained by HER2 CISH and HER2 FISH (n = 348). The dashed lines represent the cut off at a ratio of
2.0. Linear correlation coefficient (r) is 0.93
Figure 3 Plot of HER2/CEN-17 ratios obtained by HER2 CISH and PathVysion FISH (n = 350). The dashed lines represent the cut off at a
ratio of 2.0. Linear correlation coefficient (r) is 0.89
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whereas HER2/CEN-17 ratios were identical (Table 6).
Evaluation time
During the study, the evaluation time for each specimen
was recorded for HER2 CISH and PathVysion FISH
assays allowing for a comparison of evaluation times.
The mean evaluation time for HER2 CISH was 3:12
(min:sec) compared to 4:02 for PathVysion FISH (data
not shown). This difference was statistically significant
using a two-tailed, paired t-test (n = 350, p < 0.001).
Discussion
Previously published studies have reported high concor-
dance between HER2 FISH and HER2 CISH performed
in breast cancer specimens [7,15-19], however, larger
studies that validate the use of HER2 CISH have not yet
been presented. In the current investigation 365 primary
breast cancer specimens were included and an overall
HER2 status agreement close to 98% is reported when
comparing test results obtained by HER2 CISH
pharmDx™ Kit to results obtained by HER2 FISH
pharmDx™ and PathVysion HER-2 FISH DNA Probe
Kit. The study population was enriched for HercepT-
est™ IHC 2+ specimens because most testing modalities
pass on such equivocal specimens to a genetic test. For
overall agreement the lower 95% confidence interval
limits were at or above 96% in the two comparisons,
further stressing the reliability of the HER2 CISH
pharmDx™ in this comparison to the two FISH analysis
methods.
The number of HER2 amplified or HER2 positive con-
secutively collected specimens reported in this study by
the three ISH assays (10.8%, 11.4%, 11.0%) and by Her-
cepTest™ IHC (10.5%) seems to be lower than expected
based on previously published data [1] in which the
overall HER2 positivity rate was found at 22% with
observations ranging from 9%-74%. However, Ross et al.
(2009) [1] indicate that the true HER2 positivity rate
probably is in the range 15-20%, with national reference
labs and community hospitals reporting lower rates and
tertiary hospitals and cancer centers reporting slightly
higher rates.
In the current data analysis a significantly higher aver-
age CEN-17 signal counts in HER2 CISH compared to
HER2 FISH and PathVysion FISH with no significant
difference in HER2 signal counts between the three
assays were observed. This resulted in significantly
lower HER2/CEN-17 ratios observed for HER2 CISH.
There was no clinical diagnostic impact of this change
as the concordance agreement calculations revealed very
fine agreement between HER2 CISH and the two FISH
assays. In support of the good agreement the analysis of
test results for specimens having a HER2/CEN-17 CISH
ratio below 3.0 revealed that identical ratios were
obtained for HER2 CISH, HER2 FISH and PathVysion
FISH. Surprisingly, average copy numbers for both
HER2 and CEN-17 were higher for the HER2 CISH
method, whereas, HER2 CISH standard deviations
seemed to be lower for the average HER2/CEN-17 ratio,
Table 5 Mean HER2/CEN-17 ratio and signal numbers for
all specimens.
Mean N Std. Deviation
HER2/CEN-17 ratio HER2 CISH 1.64 352 1.21
HER2 FISH 1.78
a 358 1.90
PathVysion 1.77
b 361 1.83
HER2 signals HER2 CISH 74.44 352 65.65
HER2 FISH 75.58
c 358 92.92
PathVysion 71.76
d 361 76.88
CEN-17 signals HER2 CISH 43.89 352 11.98
HER2 FISH 41.20
e 358 13.09
PathVysion 41.01
f 361 21.88
Signal copy numbers were normalized to 20 nuclei
a) Significant different from CISH ratio in a two tailed, paired t-test (N = 348, P
< 0.001)
b) Significant different from CISH ratio in a two tailed, paired t-test (N = 350,
P = 0.001)
c) Not significant different from CISH HER2 signals in a two tailed, paired t-test
(N = 348, P = 0.245)
d) Not significant different from CISH HER2 signals in a two-tailed, paired t-
test (N = 350, P = 0.284)
e) Significant different from CISH CEN-17 signals in a two tailed, paired t-test
(N = 348, P < 0.001)
f) Significant different from CISH CEN-17 signals in a two-tailed, paired t-test
(N = 350, P < 0.003)
Table 6 Mean HER2/CEN-17 ratio and signal numbers for
all specimens with a HER2/CEN-17 CISH ratio below 3.
Mean N Std. Deviation
HER2/CEN-17 ratio HER2 CISH 1.28 320 0.28
HER2 FISH 1.27
a 317 0.35
PathVysion 1.28
b 319 0.40
HER2 signals HER2 CISH 55.36 320 20.62
HER2 FISH 50.90
c 317 20.59
PathVysion 50.59
d 319 26.09
CEN-17 signals HER2 CISH 42.95 320 11.44
HER2 FISH 40.35
e 317 12.28
PathVysion 39.52
f 319 14.75
Signal copy numbers were normalized to 20 nuclei
a) Not significantly different from CISH ratio in a two tailed, paired t-test (N =
316, P = 0.326)
b) Not significantly different from CISH ratio in a two tailed, paired t-test (N =
318, P = 0.982)
c) Significantly different from CISH HER2 signals in a two tailed, paired t-test
(N = 316, P < 0.001)
d) Significantly different from CISH HER2 signals in a two-tailed, paired t-test
(N = 318, P < 0.001)
e) Significantly different from CISH CEN-17 signals in a two tailed, paired t-test
(N = 316, P < 0.001)
f) Significantly different from CISH CEN-17 signals in a two-tailed, paired t-test
(N = 318, P < 0.001)
Mollerup et al. BMC Clinical Pathology 2012, 12:3
http://www.biomedcentral.com/1472-6890/12/3
Page 6 of 7HER2 and CEN-17 copy numbers compared to PathVy-
sion FISH. This could be interpreted as the HER2 CISH
assay being the most sensitive assay.
Also, there was a tendency towards differences
between HER2/CEN-17 ratios in highly amplified speci-
mens between HER2 CISH and FISH assays (see Figure
2 and 3). This is probably due to the variation in cluster
estimation and is not a problem in relation to achieving
the correct diagnosis.
As a parallel study, the slide evaluation time was com-
pared between HER2 CISH and PathVysion FISH and as
could be expected the average evaluation time for a
CISH staining was significantly shorter. This is most
likely due to the easy access to the morphological infor-
mation and hence a faster selection of areas for enu-
meration. In HER2 CISH a higher number of specimens
were reported failed in comparison to staining with
PathVysion FISH. This is likely to be due to CISH being
a new technique implemented in the US reference
laboratory and PathVysion FISH being a well established
test method at this site. With respect to HER2 CISH the
normal cells in the tissue surrounding the tumor area
can be used as internal control securing good staining
quality and preventing wrong diagnosis being based on
a failed slide.
Conclusion
From this study based on HER2 CISH and FISH data
from 365 different primary breast cancer specimens it is
c o n f i r m e dt h a tt h eF D Aa p p r o v e dHER2 CISH
pharmDx™ Kit is a reliable chromogenic alternative to
today’s FDA approved FISH techniques for HER2 gene
status determination in FFPE breast carcinoma
specimens.
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